Zobrazeno 1 - 10
of 28
pro vyhledávání: '"Ryoichi Murata"'
Autor:
Ryota Urushihara, Naoki Takezako, Takeshi Yoroidaka, Takeshi Yamashita, Ryoichi Murata, Kenji Satou, Shinji Nakao, Hiroyuki Takamatsu
Publikováno v:
eJHaem, Vol 4, Iss 1, Pp 184-191 (2023)
Abstract The prognostic value of minimal/measurable residual disease (MRD) detection in autografts of patients with multiple myeloma (MM) in an autologous stem‐cell transplantation setting has been reported. Next‐generation flow (NGF) cytometry h
Externí odkaz:
https://doaj.org/article/43040143ccae4cfa9b0a7abca25d1f0a
Autor:
TAKESHI YOROIDAKA, TAKESHI YAMASHITA, RYOICHI MURATA, KYOKO YOSHIHARA, SATOSHI YOSHIHARA, MIKIO UEDA, SHINJI NAKAO, KOSEI MATSUE, HIROYUKI TAKAMATSU
Publikováno v:
Anticancer research. 43(1)
Carfilzomib, lenalidomide, and dexamethasone (KRD) therapy is widely used for patients with relapse/refractory multiple myeloma (RRMM). However, the response in patients who underwent assessment for measurable residual disease (MRD) has not been eluc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6d73cce9127af40c7cd2649ad389f8dd
https://pubmed.ncbi.nlm.nih.gov/36585165
https://pubmed.ncbi.nlm.nih.gov/36585165
Autor:
Hiroyuki Takamatsu, Daisuke Ikeda, Toshiki Terao, Takeshi Yamashita, Ryota Urushihara, Yuzuki Hatano, Nana Hirose, Natsu Yamada, Ryoichi Murata, Toshihiro Miyamoto, Kosei Matsue
Publikováno v:
Blood. 140:1828-1829
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d1c11869ff7e96e0c2511f49b229d53e
https://doi.org/10.1182/blood-2022-158721
https://doi.org/10.1182/blood-2022-158721
Autor:
Kento Morita, Hidetaka Nambo, Toshiki Terao, Takeshi Yamashita, Shigehiro Karashima, Kotaro Yoshida, Ryoichi Murata, Toshihiro Miyamoto, Kosei Matsue, Hiroyuki Takamatsu
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 22:S52-S53
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6c60d7ad5d4bd71d8b0369d9d7d1a549
https://doi.org/10.1016/s2152-2650(22)00361-5
https://doi.org/10.1016/s2152-2650(22)00361-5
Autor:
Kazuya Kobori, Kosei Matsue, Masako Hanawa, Takeshi Yoroidaka, Momoko Fujisawa, Takeshi Yamashita, Mikio Ueda, Hiroyuki Takamatsu, Ryoichi Murata, Shinji Nakao
Publikováno v:
International Journal of Hematology. 109:377-381
We sought to determine the efficacy of a new, inexpensive, single-tube 8-color multiparameter flow cytometry (MFC) method (SRL-Flow), which is based on the EuroFlow next-generation flow (NGF) (tube 2 only), to assess minimal residual disease (MRD)-ne
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::69e4dc9ad32c00841240b0dd92de7162
https://doi.org/10.1007/s12185-019-02615-z
https://doi.org/10.1007/s12185-019-02615-z
Autor:
Yoshitaka Zaimoku, Yasushi Terasaki, Tsutomu Sato, Martin Moorhead, Shinji Nakao, Katherine A. Kong, Naoki Takezako, Kenji Yokoyama, Hiroyuki Takamatsu, Hideo Yagi, Ryoichi Murata, Malek Faham, Morio Matsumoto, Rachel K Wee, Shigeki Ito, Victoria Carlton, Kinya Ohata, Toshiro Kurokawa, Takashi Yoshida, Toshihiro Miyamoto, Kosei Matsue, Jianbiao Zheng
Publikováno v:
British Journal of Haematology. 183:664-668
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::84dd63a8387cdf35282c76d82a08f300
https://doi.org/10.1111/bjh.15002
https://doi.org/10.1111/bjh.15002
Autor:
Kosei Matsue, Tomotaka Yoshida, Malek Faham, Tsutomu Sato, Martin Moorhead, Shigeki Ito, Victoria Carlton, Hiroyuki Takamatsu, Jianbiao Zheng, Toshiro Kurokawa, Shinji Nakao, Ryoichi Murata, Kinya Ohata, Naoki Takezako, Morio Matsumoto, Hideo Yagi, Katherine A. Kong, Kozue Yokoyama, Yasushi Terasaki, Toshihiro Miyamoto
Publikováno v:
Annals of Oncology
Background Most patients with multiple myeloma (MM) are considered to be incurable, and relapse owing to minimal residual disease (MRD) is the main cause of death among these patients. Therefore, new technologies to assess deeper response are require
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::705b370a018a34ac2cb1cb736fe2f905
http://europepmc.org/articles/PMC5834061
http://europepmc.org/articles/PMC5834061
Autor:
Yoshikazu Utsu, Naoki Takezako, Emiko Sakaida, Ryoichi Murata, Motoharu Fukazawa, Kosei Matsue, Shinji Nakao, Naoya Mimura, Takeshi Yamashita, Hiroyuki Takamatsu, Masahiro Onoda, Masahiro Takeuchi, Takeshi Yoroidaka, Atsuko Yamazaki, Chiaki Nakaseko
Publikováno v:
Blood. 136:22-23
Background: Autologous stem cell transplantation (ASCT) in conjunction with novel therapeutic drugs can dramatically improve response rates and the prognoses of patients with multiple myeloma (MM). However, most patients with MM ultimately relapse du
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::99b2ec375aa566fafc3f960920ef7b03
https://doi.org/10.1182/blood-2020-137014
https://doi.org/10.1182/blood-2020-137014
Autor:
Kosei Matsue, Shinji Nakao, Takeshi Yoroidaka, Mikio Ueda, Momoko Fujisawa, Masako Hanawa, Takeshi Yamashita, Hiroyuki Takamatsu, Kazuya Kobori, Ryoichi Murata
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 19:e183-e184
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f23cb802fd9ecc52100461c919f2aa42
https://doi.org/10.1016/j.clml.2019.09.307
https://doi.org/10.1016/j.clml.2019.09.307
Autor:
Shinji Nakao, Takeshi Yamashita, Takeshi Yoroidaka, Mikio Ueda, Hiroyuki Takamatsu, Kosei Matsue, Ryoichi Murata
Publikováno v:
Blood. 134:3083-3083
Background: The rate of complete response (CR) in multiple myeloma (MM) has dramatically increased because of the development of novel agents. In addition, the development of methods for measuring minimal residual disease (MRD), such as multiparamete
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e2c358ba40574878969f40032cf6c41f
https://doi.org/10.1182/blood-2019-122398
https://doi.org/10.1182/blood-2019-122398